Company: LENZ
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001193125-25-100630
Chunk: 20

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 20
---
 the audits and the audit fees and approve all non-audit and tax services to be performed by the independent auditor; |

| • |     | evaluate the independence and qualifications of our independent registered public accounting firm; |

| • |     | review our financial statements, and discuss with management and our independent registered public accounting firm the results of the annual audit and the quarterly reviews; |

-10-

| • |     | review and discuss with management and our independent registered public accounting firm the quality and adequacy of our internal controls and our disclosure controls and procedures; |

| • |     | discuss with management our procedures regarding the presentation of our financial information, and review earnings press releases and guidance; |

| • |     | oversee the design, implementation and performance of our internal audit function, if any; |

| • |     | set hiring policies with regard to the hiring of employees and former employees of our independent auditor and oversee compliance with such policies; |

| • |     | review, approve and monitor related party transactions; |

| • |     | adopt and oversee procedures to address complaints regarding accounting, internal accounting controls and auditing matters, including confidential, anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters; |

| • |     | review and discuss with management and our independent auditor the adequacy and effectiveness of our legal, regulatory and ethical compliance programs; and |

| • |     | review and discuss with management and our independent auditor our guidelines and policies to identify, monitor and address enterprise risks, including major financial risks exposures and risks and exposures associated with cybersecurity, information security and privacy matters. |

Our audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq, available on our website at https://ir.lenz-tx.com/corporate-governance.Following the closing of the Merger through December 31, 2024, our audit committee held four meetings. Compensation Committee The members of our compensation committee are Frederic Guerard, Kimberlee C. Drapkin and Shelley Thunen, and Dr. Guerard serves as the chairperson of the compensation committee. Our board of directors has determined that each of the members of the compensation committee is a non-employeedirector, as defined in Rule 16b-3promulgated under the Exchange Act and satisfies the independence requirements of Nasdaq. The functions of our compensation committee include, among other things, the authority and responsibility to:

| • |     | review,